1. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. Issue 8 (15th July 2009) Authors: Grabar, P Bohanec; Rozman, B; Logar, D; Praprotnik, S; Dolžan, V Journal: Annals of the rheumatic diseases Issue: Volume 68:Issue 8(2009) Page Start: 1367 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT). Issue 12 (21st November 2003) Authors: Leeb, B F; Bird, H A; Nesher, G; Andel, I; Hueber, W; Logar, D; Montecucco, C M; Rovensky, J; Sautner, J; Sonnenblick, M Journal: Annals of the rheumatic diseases Issue: Volume 62:Issue 12(2003) Page Start: 1189 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Leflunomide and hypertension. Issue 6 (1st June 2002) Authors: Rozman, B; Praprotnik, S; Logar, D; Tomšič, M; Hojnik, M; Kos-Golja, M; Accetto, R; Dolenc, P Journal: Annals of the rheumatic diseases Issue: Volume 61:Issue 6(2002) Page Start: 567 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Possible association between anti-Ro antibodies and myocarditis or cardiac conduction defects in adults with systemic lupus erythematosus. Issue 8 (August 1990) Authors: Logar, D; Kveder, T; Rozman, B; Dobovisek, J Journal: Annals of the rheumatic diseases Issue: Volume 49:Issue 8(1990) Page Start: 627 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗